A Study of the Safety and Effectiveness of CNTO 328 (Anti IL-6 Monoclonal Antibody) in Patients With Relapsed or Refractory Multiple Myeloma
This study has been completed.
Sponsor:
Centocor, Inc.
Information provided by (Responsible Party):
Centocor, Inc.
ClinicalTrials.gov Identifier:
NCT00402181
First received: November 17, 2006
Last updated: January 31, 2013
Last verified: January 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been completed. |
|---|---|
| Study Completion Date: | July 2009 |
| Primary Completion Date: | July 2009 (Final data collection date for primary outcome measure) |
| Certification or Request for Extension to Delay Results Received: | January 31, 2013 |